Abstract: Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines.

Abstract: Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines.

Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.

Abstract: Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines.

Abstract: The present invention describes methods of prognosticating patient survival based on an analysis of the ZEB1 gene or gene product. The present invention also describes methods of selecting and/or selecting various therapies based on the analysis of ZEB1, IDH1, PTEN, MGMT and/or RET. Further describes are systems for analyzing ZEB1, IDH1, PTEN, MGMT and/or RET as well as selecting and/or selecting the therapies.

Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.

Abstract: An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.

Abstract: The present invention describes methods of prognosticating patient survival based on an analysis of the ZEB1 gene or gene product. The present invention also describes methods of selecting and/or selecting various therapies based on the analysis of ZEB1, IDH1, PTEN, MGMT and/or RET. Further describes are systems for analyzing ZEB1, IDH1, PTEN, MGMT and/or RET as well as selecting and/or selecting the therapies.

Abstract: The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of ?-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions.

Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.

Abstract: An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO: 1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO: 1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO: 13). The immunogens can be used in compositions and in the treatment of disorders.

Abstract: This invention relates to uses of conjugates of triptolide nanoprodrugs in cancer immunotherapy, specifically compound such as D-I or D-II wherein X1 is a antioxidant, an anti-inflammatory or an anti-cancer agent and nanospheres thereof, and A is be selected from the group consisting of branched and unbranched alkyl, branched and unbranched alkenyl, branched and unbranched alkynyl, heteroatom-containing branched and unbranched alkyl, heteroatom-containing branched and unbranched alkenyl, heteroatom-containing branched and unbranched alkynyl, aryl, cyclic aliphatic, cyclic aromatic, heterocyclic, and aromatic heterocyclic groups.

Abstract: Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines.

Abstract: The present invention describes methods of delivering derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) and nanospheres thereof as well as therapeutic agents to the injured brain tissue in subjects with traumatic brain injury. The invention also provides methods of treating traumatic brain injury and related conditions. The invention further provides methods of diagnosing traumatic brain injury.

Abstract: Compositions of multipeptide vaccines including tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating ovarian cancers using such vaccines.

Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.

Abstract: An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.

Abstract: The present invention is directed to multiple a-lipoic acid-containing hydrophobic compounds (mALAs) capable of acting as scavengers of free radicals, metals and reactive oxygen species (ROS). Methods of synthesizing novel antioxidant mALAs, spontaneous emulsification or nanoprecipitaion thereof to produce antioxidant nanospheres and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are also described. Another aspect of this invention is the use of these antioxidant nanospheres for the preparation of antioxidant particulate delivery system of therapeutic agents.

Abstract: Method of stimulating an immune response (e.g., to treat cancer) include administering to a patient a composition including dendritic cells that present cancer stem cell antigens. Compositions including cancer stem cell antigens are also provided herein.

Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.